These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 30145094)

  • 1. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
    Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
    J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177.
    Carneiro FS; Giachini FR; Carneiro ZN; Lima VV; Ergul A; Webb RC; Tostes RC
    J Sex Med; 2010 Nov; 7(11):3620-34. PubMed ID: 20807325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Intensity Extracorporeal Shock Wave Therapy Improves Erectile Function in a Model of Type II Diabetes Independently of NO/cGMP Pathway.
    Assaly-Kaddoum R; Giuliano F; Laurin M; Gorny D; Kergoat M; Bernabé J; Vardi Y; Alexandre L; Behr-Roussel D
    J Urol; 2016 Sep; 196(3):950-6. PubMed ID: 27038770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PnPP-19 Peptide Restores Erectile Function in Hypertensive and Diabetic Animals Through Intravenous and Topical Administration.
    Nunes da Silva C; Nunes KP; De Marco Almeida F; Silva Costa FL; Borges PV; Lacativa P; Pimenta AMC; Elena de Lima M
    J Sex Med; 2019 Mar; 16(3):365-374. PubMed ID: 30773502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder and erectile dysfunctions in the Type 2 diabetic Goto-Kakizaki rat.
    Oger-Roussel S; Behr-Roussel D; Caisey S; Kergoat M; Charon C; Audet A; Bernabé J; Alexandre L; Giuliano F
    Am J Physiol Regul Integr Comp Physiol; 2014 Jan; 306(2):R108-17. PubMed ID: 24305064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Strategy With Oral Phosphodiesterase Type 5 Inhibition and Intracavernosal Implantation of Mesenchymal Stem Cells Is Superior to Individual Approaches in the Recovery of Erectile and Cavernosal Functions After Cavernous Nerve Injury in Rats.
    Martínez-Salamanca JI; Zurita M; Costa C; Martínez-Salamanca E; Fernández A; Castela A; Vaquero J; Carballido J; Angulo J
    J Sex Med; 2016 Jan; 13(1):1-11. PubMed ID: 26755080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of Toll-Like Receptor 4 Attenuates Erectile Dysfunction in Diabetic Rats.
    Nunes KP; de Oliveira AA; Szasz T; Biancardi VC; Webb RC
    J Sex Med; 2018 Sep; 15(9):1235-1245. PubMed ID: 30145096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH;
    J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
    Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis.
    Behr-Roussel D; Gorny D; Mevel K; Caisey S; Bernabé J; Burgess G; Wayman C; Alexandre L; Giuliano F
    Eur Urol; 2005 Jan; 47(1):87-91. PubMed ID: 15582254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STIM/Orai Inhibition as a Strategy for Alleviating Diabetic Erectile Dysfunction Through Modulation of Rat and Human Penile Tissue Contractility and in vivo Potentiation of Erectile Responses.
    Sevilleja-Ortiz A; El Assar M; García-Gómez B; La Fuente JM; Alonso-Isa M; Romero-Otero J; Martínez-Salamanca JI; Fernández A; Rodríguez-Mañas L; Angulo J
    J Sex Med; 2022 Dec; 19(12):1733-1749. PubMed ID: 36195535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α
    Martínez-Salamanca JI; La Fuente JM; Martínez-Salamanca E; Fernández A; Pepe-Cardoso AJ; Louro N; Carballido J; Angulo J
    J Sex Med; 2016 Dec; 13(12):1844-1857. PubMed ID: 27864032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P144, A TGF-β1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats.
    Li WJ; Wang H; Zhou J; Li B; Zhang J; Lu M; Wang Z
    J Sex Med; 2013 Dec; 10(12):2942-51. PubMed ID: 24134744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
    Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
    Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of BKCa Channel Opener LDD175 on Erectile Function in an In Vivo Diabetic Rat Model.
    Sung HH; Kang SJ; Chae MR; Kim HK; Park JK; Kim CY; Lee SW
    J Sex Med; 2017 Jan; 14(1):59-68. PubMed ID: 27989487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes.
    Zhang XH; Filippi S; Morelli A; Vignozzi L; Luconi M; Donati S; Forti G; Maggi M
    J Sex Med; 2006 Mar; 3(2):253-64; discussion 264-5, author reply 265-6. PubMed ID: 16490018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.